NewCardio Inc. a cardiac diagnostic technology provider, signed entered into a new line of credit with three of its existing shareholders, one of which is represented about the Board of Directors, to strengthen its financial position. This will allow the company further time to fully commercialize its lead solution, Qtinno.
The credit facility is component of a series of steps created to improve the company’s ability to identify and attract potential strategic relationships and/or investors that is intended to enable the company to maximize the value to be derived through continued development of its 3D platform technologies.
NewCardio Inc., a development-stage cardiac diagnostic organization, focuses on the research, improvement, and commercialization of proprietary software platform technologies solutions for the non-invasive diagnosis and monitoring of cardiovascular disease, as well as for the cardiac safety assessment of drugs under development.
No related posts.